GNLX
Price
$5.71
Change
+$0.34 (+6.34%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
202.47M
26 days until earnings call
SYRE
Price
$22.48
Change
+$0.24 (+1.08%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
1.74B
19 days until earnings call
Interact to see
Advertisement

GNLX vs SYRE

Header iconGNLX vs SYRE Comparison
Open Charts GNLX vs SYREBanner chart's image
Genelux
Price$5.71
Change+$0.34 (+6.34%)
Volume$1.69K
Capitalization202.47M
Spyre Therapeutics
Price$22.48
Change+$0.24 (+1.08%)
Volume$46.04K
Capitalization1.74B
GNLX vs SYRE Comparison Chart in %
GNLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GNLX vs. SYRE commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNLX is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (GNLX: $5.36 vs. SYRE: $22.24)
Brand notoriety: GNLX and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNLX: 125% vs. SYRE: 294%
Market capitalization -- GNLX: $216.06M vs. SYRE: $1.74B
GNLX [@Biotechnology] is valued at $216.06M. SYRE’s [@Biotechnology] market capitalization is $1.74B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNLX’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • GNLX’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, both GNLX and SYRE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNLX’s TA Score shows that 2 TA indicator(s) are bullish while SYRE’s TA Score has 5 bullish TA indicator(s).

  • GNLX’s TA Score: 2 bullish, 4 bearish.
  • SYRE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than GNLX.

Price Growth

GNLX (@Biotechnology) experienced а -5.47% price change this week, while SYRE (@Biotechnology) price change was +5.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +16.02%, and the average quarterly price growth was +79.42%.

Reported Earning Dates

GNLX is expected to report earnings on Nov 12, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.74B) has a higher market cap than GNLX($202M). GNLX YTD gains are higher at: 127.119 vs. SYRE (-4.467). GNLX has higher annual earnings (EBITDA): -29.74M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. GNLX (28M). SYRE has less debt than GNLX: SYRE (0) vs GNLX (1.71M). GNLX (0) and SYRE (0) have equivalent revenues.
GNLXSYREGNLX / SYRE
Capitalization202M1.74B12%
EBITDA-29.74M-222.15M13%
Gain YTD127.119-4.467-2,845%
P/E RatioN/A1.72-
Revenue00-
Total Cash28M527M5%
Total Debt1.71M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
26
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
93
P/E GROWTH RATING
1..100
80
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
GNLXSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 22 days ago
88%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
GNLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WPNDF0.11N/A
+2.90%
Wishpond Technologies Ltd.
ASHTF70.810.68
+0.97%
Ashtead Group PLC
SLFPY11.400.09
+0.80%
ABERDEEN GROUP PLC
BKOR27.20N/A
N/A
Oak Ridge Financial Services, Inc.
CGJTF59.07-0.41
-0.68%
Cargojet, Inc.

GNLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNLX has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if GNLX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNLX
1D Price
Change %
GNLX100%
-1.47%
SYRE - GNLX
36%
Loosely correlated
+0.23%
BHVN - GNLX
33%
Loosely correlated
-5.07%
RXRX - GNLX
33%
Poorly correlated
-6.33%
SNSE - GNLX
32%
Poorly correlated
+28.52%
ATYR - GNLX
32%
Poorly correlated
-1.96%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.23%
CGON - SYRE
59%
Loosely correlated
-2.79%
APGE - SYRE
58%
Loosely correlated
-4.39%
IDYA - SYRE
56%
Loosely correlated
-2.43%
NRIX - SYRE
55%
Loosely correlated
-3.09%
RGNX - SYRE
55%
Loosely correlated
+0.33%
More